XLO News and Press, Xilio Therapeutics Inc. From 11/07/25

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-1...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a late-breaking poster presenta...

WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the Societ...

2025-09-09 11:00:51 ET Xilio Therapeutics (NASDAQ: XLO ) has begun patient dosing in the Phase 2 portion of its ongoing trial evaluating efarindodekin alfa (XTX301) , a tumor-activated IL-12 designed to selectively activate in the tumor microenvironment. The study will assess XTX301...

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics,&...

2025-08-14 08:09:49 ET More on Xilio Therapeutics Xilio Therapeutics announces pricing of $50 million public offering Xilio Therapeutics announces public offering; shares down Seeking Alpha’s Quant Rating on Xilio Therapeutics Historical earnings data ...

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track with plans to nominate first deve...

Century Therapeutics Inc. (IPSC) is expected to report $-0.38 for Q2 2025 Birchtech Corp Com (BCHT) is expected to report for Q2 2025 Cellectar Biosciences Inc. (CLRB) is expected to report $-3.6 for Q2 2025 Acuren Corporation (TIC) is expected to report for quarter end 2025-06-30 ...

Xilio Therapeutics Inc. (XLO) is expected to report $-0.08 for Q2 2025